Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers
2016
Leonard D. Goldstein | James Lee | Florian Gnad | Christiaan Klijn | Annalisa Schaub | Jens Reeder | Anneleen Daemen | Corey E. Bakalarski | Thomas Holcomb | David S. Shames | Ryan J. Hartmaier | Juliann Chmielecki | Somasekar Seshagiri | Robert Gentleman | David Stokoe
The Nrf2 pathway is frequently activated in human cancers through mutations in Nrf2 or its negative regulator KEAP1. Using a cell-line-derived gene signature for Nrf2 pathway activation, we found that some tumors show high Nrf2 activity in the absence of known mutations in the pathway. An analysis of splice variants in oncogenes revealed that such tumors express abnormal transcript variants from the NFE2L2 gene (encoding Nrf2) that lack exon 2, or exons 2 and 3, and encode Nrf2 protein isoforms missing the KEAP1 interaction domain. The Nrf2 alterations result in the loss of interaction with KEAP1, Nrf2 stabilization, induction of a Nrf2 transcriptional response, and Nrf2 pathway dependence. In all analyzed cases, transcript variants were the result of heterozygous genomic microdeletions. Thus, we identify an alternative mechanism for Nrf2 pathway activation in human tumors and elucidate its functional consequences.
Show more [+] Less [-]Bibliographic information
This bibliographic record has been provided by Directory of Open Access Journals
